These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 35698292)

  • 1. Idarubicin-Loaded DEB-TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score-matching analysis.
    Fan W; Zhu B; Yue S; Zheng X; Zou X; Li F; Qiao L; Wu Y; Xue M; Wang H; Tang Y; Li J
    Cancer Med; 2023 Jan; 12(1):61-72. PubMed ID: 35698292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idarubicin versus epirubicin in drug-eluting beads-transarterial chemoembolization for treating hepatocellular carcinoma: A real-world retrospective study.
    Zhao C; Yan H; Xiang Z; Wang H; Li M; Huang M
    Invest New Drugs; 2023 Aug; 41(4):617-626. PubMed ID: 37434023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced hepatocellular carcinoma treated by transcatheter arterial chemoembolization with drug-eluting beads plus lenvatinib versus sorafenib, a propensity score matching retrospective study.
    Xue M; Wu Y; Zhu B; Zou X; Fan W; Li J
    Am J Cancer Res; 2021; 11(12):6107-6118. PubMed ID: 35018245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.
    Ando Y; Kawaoka T; Amioka K; Naruto K; Ogawa Y; Yoshikawa Y; Kikukawa C; Kosaka Y; Uchikawa S; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Takahashi S; Imamura M; Chayama K; Aikata H
    Oncology; 2021; 99(8):507-517. PubMed ID: 33946070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenvatinib plus drug-eluting bead transarterial chemoembolization with/without hepatic arterial infusion chemotherapy for hepatocellular carcinoma larger than 7 cm with major portal vein tumor thrombosis: a multicenter retrospective cohort study.
    Cai M; Liang L; Zhang J; Chen N; Huang W; Guo Y; Hong X; Lin L; Liu Y; Dan C; Deng H; Liu X; Zhou J; Chen Y; Chen H; Zhu K
    Int J Surg; 2024 Jun; 110(12):7860-70. PubMed ID: 38869974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study.
    Jin ZC; Zhong BY; Chen JJ; Zhu HD; Sun JH; Yin GW; Ge NJ; Luo B; Ding WB; Li WH; Chen L; Wang YQ; Zhu XL; Yang WZ; Li HL; Teng GJ;
    Eur Radiol; 2023 Dec; 33(12):8669-8681. PubMed ID: 37368105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study.
    Xia D; Bai W; Wang E; Li J; Chen X; Wang Z; Huang M; Huang M; Sun J; Yang W; Lin Z; Wu J; Li Z; Yang S; Zhu X; Chen Z; Zhang Y; Fan W; Mai Q; Ding R; Nie C; Feng L; Li X; Huang W; Sun J; Wang Q; Lv Y; Li X; Luo B; Wang Z; Yuan J; Guo W; Li K; Li B; Li R; Yin Z; Xia J; Han G
    Liver Cancer; 2022 Jul; 11(4):368-382. PubMed ID: 35978600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study.
    Tang Z; Bai T; Wei T; Wang X; Chen J; Ye J; Li S; Wei M; Li X; Lin Y; Tang J; Li L; Wu F
    BMC Cancer; 2024 Jun; 24(1):717. PubMed ID: 38862932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficiency and Stability of Transarterial Chemoembolization Combined With or Without Lenvatinib for Unresectable Hepatocellular Carcinoma.
    Zong Z; Tang R; Li M; Xiong X; Li D; Fan J; Ye W; Xue C
    Turk J Gastroenterol; 2024 Mar; 35(3):212-222. PubMed ID: 39128062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
    Hu H; Duan Z; Long X; Hertzanu Y; Shi H; Liu S; Yang Z
    PLoS One; 2014; 9(5):e96620. PubMed ID: 24817002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
    Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
    Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib plus drug-eluting bead transarterial chemoembolization for early intrahepatic stage-progressed advanced hepatocellular carcinoma refractory to conventional transarterial chemoembolization.
    Fan W; Zhu B; Zheng X; Yue S; Lu M; Fan H; Qiao L; Li F; Yuan G; Wu Y; Zou X; Wang H; Xue M; Li J
    J Cancer Res Clin Oncol; 2023 May; 149(5):1873-1882. PubMed ID: 35788728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.
    Zou X; Xu Q; You R; Yin G
    Cancer Med; 2023 May; 12(10):11315-11333. PubMed ID: 36951443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.
    Diao L; Wang C; You R; Leng B; Yu Z; Xu Q; Cheng Y; Yin G
    J Gastroenterol Hepatol; 2024 Apr; 39(4):746-753. PubMed ID: 38240156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sunitinib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
    Chen J; Zhou C; Long Y; Yin X
    Tumour Biol; 2015 Jan; 36(1):183-91. PubMed ID: 25217986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH).
    Peng Z; Fan W; Zhu B; Wang G; Sun J; Xiao C; Huang F; Tang R; Cheng Y; Huang Z; Liang Y; Fan H; Qiao L; Li F; Zhuang W; Peng B; Wang J; Li J; Kuang M
    J Clin Oncol; 2023 Jan; 41(1):117-127. PubMed ID: 35921605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
    Lencioni R; Llovet JM; Han G; Tak WY; Yang J; Guglielmi A; Paik SW; Reig M; Kim DY; Chau GY; Luca A; Del Arbol LR; Leberre MA; Niu W; Nicholson K; Meinhardt G; Bruix J
    J Hepatol; 2016 May; 64(5):1090-1098. PubMed ID: 26809111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of transarterial chemoembolization plus lenvatinib in the treatment of advanced hepatocellular carcinoma: A meta-analysis.
    Li D; Liu S; Cheng C; Xu L; Zhao P
    Medicine (Baltimore); 2023 Sep; 102(35):e34811. PubMed ID: 37657057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses.
    Choi GH; Shim JH; Kim MJ; Ryu MH; Ryoo BY; Kang YK; Shin YM; Kim KM; Lim YS; Lee HC
    Radiology; 2013 Nov; 269(2):603-11. PubMed ID: 23864102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib.
    Wang J; Zhao M; Han G; Han X; Shi J; Mi L; Li N; Yin X; Duan X; Hou J; Yin F
    Technol Cancer Res Treat; 2023; 22():15330338231166765. PubMed ID: 37161343
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.